Actelion Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3046)
◆英語タイトル:Actelion Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3046
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Actelion Pharmaceuticals Ltd (Actelion), subsidiary of Johnson & Johnson is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.

Actelion Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Enamine Expands Agreement with Actelion 14
SynAging Extends Agreement with Actelion Pharma 15
Handok Enters into Agreement with Actelion Pharmaceuticals 16
Actelion Forms Joint Venture with Max Planck Society 17
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18
Licensing Agreements 19
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 20
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 21
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 22
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 24
Equity Offering 25
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 25
Asset Transactions 26
Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 26
Acquisition 27
Johnson & Johnson Acquires Actelion for USD30 Billion 27
Actelion Plans to Acquire ZS Pharma 29
Actelion Rejects Acquisition Offer from Shire 30
Tetraphase Pharma May Sell Itself 31
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 32
Actelion Pharmaceuticals Ltd – Key Competitors 34
Actelion Pharmaceuticals Ltd – Key Employees 35
Actelion Pharmaceuticals Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 40
Financial Announcements 40
Feb 14, 2017: Actelion announces excellent financial results for 2016 40
Corporate Communications 44
Aug 06, 2018: Alzheon appoints former IVAX president, Neil Flanzraich, JD, as vice chairman of board of directors 44
Jun 09, 2017: Publication of Idorsia’s prospectus relating to the listing of Idorsia on SIX Swiss Exchange 45
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 47
Other Significant Developments 48
May 22, 2017: Actelion provides an update on the progress towards launching Idorsia – Key results for pipeline assets to be developed by Idorsia 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actelion Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Enamine Expands Agreement with Actelion 14
SynAging Extends Agreement with Actelion Pharma 15
Handok Enters into Agreement with Actelion Pharmaceuticals 16
Actelion Forms Joint Venture with Max Planck Society 17
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 18
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 19
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 20
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 21
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 22
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 24
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 25
Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma 26
Johnson & Johnson Acquires Actelion for USD30 Billion 27
Actelion Plans to Acquire ZS Pharma 29
Actelion Rejects Acquisition Offer from Shire 30
Tetraphase Pharma May Sell Itself 31
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 32
Actelion Pharmaceuticals Ltd, Key Competitors 34
Actelion Pharmaceuticals Ltd, Key Employees 35
Actelion Pharmaceuticals Ltd, Subsidiaries 36

List of Figures
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Actelion Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Actelion Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報(Actelion Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆